Skip to main content
CGC
NASDAQ Life Sciences

Canopy Growth Q2 Net Loss Widens to C$40.7M; Material Weakness Persists

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Pharmaceutical Stocks · Healthcare
Sentiment info
Negative
Importance info
8
Price
$0.7
Mkt Cap
$301.247M
52W Low
$0.641
52W High
$2.38
52W Position info
9.2% above low
Off High info
71% below high
Rel. Volume info
1.1× avg
Market data snapshot near publication time

CGC is trading near its 52-week low of $0.641 (9.2% above the low).

Summary

Canopy Growth's Q2 FY2027 net loss widened to C$40.7M from C$5.0M, mostly on non-cash fair value swings in its Canopy USA holdings, while revenue grew 22% to C$81.4M. The previously disclosed material weakness in internal controls remains unremediated.


Key Events · Earnings and Guidance · CGC

  • Net Loss Widens on Non-Cash Marks

    Q2 FY2027 net loss was C$40.7M versus C$5.0M a year earlier, driven by a C$35.8M swing in fair value changes on Canopy USA related assets (C$11.9M expense vs. C$23.9M income).

  • Revenue Up 22% to C$81.4M

    Net revenue rose to C$81.4M from C$66.7M, with international cannabis up 141% to C$12.3M; Adjusted EBITDA loss narrowed to C$2.9M from C$3.0M.

  • Material Weakness Still Unremediated

    The equity-versus-liability classification weakness in USD-denominated warrants persists, and disclosure controls were concluded not effective as of September 30, 2026.

  • Cash Falls C$117.3M in Six Months

    Cash and equivalents ended at C$247.3M versus C$364.7M at March 31, 2026, with C$37.6M used in operations and C$71.7M moved into short-term investments.


Analysis · CGC · Life Sciences

The headline loss ballooned to C$40.7M from C$5.0M a year ago, but the swing is almost entirely non-cash: a C$35.8M year-over-year reversal in fair value marks on the Canopy USA assets (a C$11.9M expense this quarter versus a C$23.9M gain a year ago, driven by the TerrAscend share price). Revenue growth of 22% to C$81.4M and a slightly narrower Adjusted EBITDA loss of C$2.9M show the core cannabis business improving. Against that, the company still carries an unremediated material weakness in internal controls over equity-versus-liability classification of USD-denominated warrants, and its disclosure controls were concluded not effective at September 30, 2026 — a governance overhang on top of a C$247.3M cash balance that fell by C$117.3M in six months. Acreage remains in default on its credit agreement, with forbearance now running to January 31, 2027.

How filings like this one have moved

In the 30 days to Nov 17, 2026, 48.3% of the 2133 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.28%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, CGC was trading at $0.70 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $301.2M. The 52-week trading range was $0.64 to $2.38. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

CGC - Latest Insights

CGC
Nov 06, 2026, 12:47 PM EST
Source: Benzinga
Importance Score:
7
Price at Filing: $0.6144
Real-time Price: $0.4436 info
Change: -$0.1708 (-28%) info
Market Cap: $200.146M info
CGC
Nov 06, 2026, 7:00 AM EST
Source: BusinessWire
Importance Score:
7
Price at Filing: $0.690
Real-time Price: $0.4436 info
Change: -$0.2464 (-36%) info
Market Cap: $200.146M info
CGC
Oct 23, 2026, 5:19 PM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $0.673
Real-time Price: $0.4436 info
Change: -$0.2294 (-34%) info
Market Cap: $200.146M info
CGC
Oct 16, 2026, 5:00 PM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $0.7183
Real-time Price: $0.4436 info
Change: -$0.2747 (-38%) info
Market Cap: $200.146M info
CGC
Aug 07, 2026, 4:50 PM EDT
Filing Type: DEF 14A
Importance Score:
8
Price at Filing: $0.962
Real-time Price: $0.4436 info
Change: -$0.5184 (-54%) info
Market Cap: $200.146M info